ALSO READUSFDA audit finds no flaws in Cadila Healthcare Moraiya unit Cadila's US business hopes soar on Moraiya plant approval Cadila Healthcare says Changodar plant has got no USFDA observation Cadila Healthcare's Changodar plant gets no USFDA observation; shares rise Zydus Cadila gets USFDA nod to market anti-dementia drug
Drug firm Cadila Healthcare on Thursday said the US health regulator has issued no observations after completion of inspection of its Moraiya plant in Gujarat.
The United States Food and Drug Administration (USFDA) has inspected the company's Moraiya facility from August 31-September 7, 2017, Cadila Healthcare said in a statement.
"At the end of the inspection, no observation (483) is issued", it added.
As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injurious to health.
The FDA Form 483 notifies the company's management of objectionable conditions.
Shares of Cadila Healthcare on Thursday closed 3.41% higher at Rs 512.60 per scrip on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)